Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Oncotelic Therapeutics ( (OTLC) ).
On May 1, 2026, Oncotelic Therapeutics completed a merger in which its affiliate Holdings was merged into Merger Sub, making Merger Sub a wholly owned subsidiary of Lunai, and in exchange Oncotelic received five shares of Lunai’s Series B preferred stock with an aggregate stated value of $12.5 million and a broad, perpetual license to exploit the transferred intellectual property outside the biodefense and Alzheimer’s disease fields. The transaction, which involved no cash consideration, strengthens Oncotelic’s strategic access to key intellectual property while, under a related asset transfer agreement, the company also agreed to issue Autotelic, Inc. common stock equal to 10% of Oncotelic’s fully diluted shares upon a future uplisting to a major U.S. exchange, potentially reshaping its capital structure and ownership profile.
Spark’s Take on OTLC Stock
According to Spark, TipRanks’ AI Analyst, OTLC is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, persistent operating losses, and ongoing cash burn) and a bearish price trend below key moving averages. Corporate events provide some upside via pipeline/platform progress and partnerships, but the 2025 profit surge appears largely non-cash and valuation metrics provided do not offer clear support.
To see Spark’s full report on OTLC stock, click here.
More about Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. operates in the biopharmaceutical sector, focusing on the development and commercialization of therapeutic assets. The company structures its operations through various subsidiaries and equity positions in related entities, using strategic transactions to expand its portfolio and optimize the use of intellectual property across different therapeutic fields.
Average Trading Volume: 337,528
Technical Sentiment Signal: Sell
Current Market Cap: $16.7M
Learn more about OTLC stock on TipRanks’ Stock Analysis page.